沃森生物(300142.SZ)為推進嘉和生物擬於境外上市的股權重組方案 BVI子公司簽署JHBP (CY)股東協議等文件
格隆匯8月24日丨沃森生物(300142.SZ)公佈，2019年7月26日，公司第三屆董事會第三十八次會議和第三屆監事會第二十七次會議審議通過了《關於BVI子公司簽署JHBP (CY) HO LDINGS LIMITED股東協議等文件的議案》，為推進實施公司參股公司嘉和生物藥業有限公司(“嘉和生物”)擬於境外上市的股權重組方案，公司BVI子公司Walga Biotechnology Limited(中文名：沃嘉生物技術有限公司，“BVI子公司”)擬與JHBP (CY) HOLDINGS LIMITED(“JHBP (CY)”)以及嘉和生物其他境內股東的境外關聯方等主體簽署《JHBP (CY) HO LDIN GS LIMITED修訂並重述股東協議》及相關文件，以明確BVI子公司作為JHBP (CY)股東的相關股東權利及義務。近日，協議各方已完成了協議的簽署。
鑑於公司根據《JHBP (CY) HOLDINGS LIMITED修訂並重述股東協議》擬委派公司董事長李雲春擔任JHBP (CY)董事，故JHBP (CY)為公司的關聯方，此次BVI子公司簽署《JHBP (CY) HO LDINGS LIMITED修訂並重述股東協議》構成關聯交易。公司董事會在審議本議案時，李雲春迴避表決，本議案由其他非關聯董事表決同意通過。
此次BVI子公司與JHBP (CY)以及嘉和生物其他境內股東的境外關聯方簽署《JHBP (CY) HOLDINGS LIMITED修訂並重述股東協議》及相關文件無需提交公司股東大會審議，不構成《上市公司重大資產重組管理辦法》規定的重大資產重組情形。
此次BVI子公司簽署本股東協議等相關文件係為執行嘉和生物境外重組步驟，為明確其作為JHBP (CY)股東的權利、義務，以及為辦理BVI子公司向JHBP (C Y)出資相關境內審批手續，不會對公司財務狀況和經營狀況產生不利影響，不存在損害上市公司及股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
